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The Northern Region Young Persons’ Malignant Disease Registry
(NRYPMDR) established in 1968 (Craft et al, 1987), was one of
the first population-based childhood cancer registries in the UK,
the earliest being the Manchester Children’s Tumour Registry
(Birch, 1988). It is the only specialist registry in the UK currently
recording cancer in young adults aged under 25 years. This study
aimed to document incidence and survival from cancer in children
(aged 0–14 years) and young adults (aged 15–24 years) diagnosed
in the North of England during the period 1968 to 1995, and to
examine changes in incidence rates and survival over time.
PATIENTS AND METHODS
The Northern Region Young Persons’ Malignant
Disease Registry
The NRYPMDR was established in 1968 and covers the Northern
Region of England as defined by 1972 Boundary Commission
(Compten, 1972), excluding the district of Barrow-in-Furness. The
study region (Figure 1) has a population of 3.1 million, with
approximately 37 000 live births per year and covers an area of
15 337 km2 with a mixture of urban and rural areas. Population
density varies widely; Northumberland and Cumbria are the two
most sparsely populated counties in England, while Tyne & Wear
is one of the most densely populated (HMSO, 1996). The popula-
tion is predominantly Caucasian and ethnic minorities account
for under 2%. Data on malignancies and benign central nervous
systems (CNS) tumours in children resident in the region at time
of diagnosis have been collected prospectively since 1968 and
incidence and survival up to 1982 have been reported previously
(Craft et al, 1987). Cancers in the 15 to 24 year age group for the
period 1968 to 1985 were identified retrospectively in 1985 (Craft
et al, 1993) and have been collected prospectively since then.
Cases are identified from multiple sources: consultants in the
region notify the registry of any malignancies in children and,
young adults. Data are periodically cross-checked with regional
and national cancer registries; death certificates and hospital
admissions are scrutinized regularly. The registry liaises with the
National Children’s Tumour Registry in Oxford and the United
Kingdom Children’s Cancer Study Group to ensure information is
as accurate and complete as possible. Ascertainment is believed
to be at least 98% complete. Responsible clinicians and general
practitioners are contacted at regular intervals (approximately
6-monthly) to determine patients’ current vital status. The registry
does not record cervical intra-epithelial neoplasia.
Data collected by the NRYPMDR include demographic details
(such as age, gender, residential address) and details of diagnosis
and treatment. A copy of the birth certificate is obtained by the
registry and cases undergo central diagnostic and pathological
review. Tumours are coded for morphology and primary site using
the International Classification of Diseases for Oncology (ICDO-
2) (WHO, 1990). Cases are grouped according to a modified
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(ICCC) (Kramarova et al, 1996). The modifications are as follows:
1. Germ cell and gonadal tumours (group Xc) is subdivided into
seminoma (M9060–9064), testicular endodermal tumours
(M9070–9079), testicular teratoma (M9080–9102), and germ
cell tumours of the ovary.
2. Other carcinomas (group Xf) are subdivided into lung
(C34.0–34.9), colorectal (C18.0–20.9), breast (C50.0–50.9),
cervix (C53.8–53.9), and other sites
3. Langerhans cell histiocytosis (LCH) is reported as a separate
group and not included in further analysis.
Data verification programs are applied to check the validity of
morphology, primary site and gender combinations. Second and
subsequent primary cancers (51), tumours of benign or uncertain
behavior (56) and carcinomas in situ (8) were excluded from the
analyses.
Data analysis
Incidence rates were calculated based on mid-year population
estimates for the study region obtained from the National Health
Service Executive, Durham. Adjustments for the population of
Barrow-in-Furness were made based on census estimates. Age-stan-
dardized rates (ASR) were calculated based on the standard world
population (Smith, 1992). Cumulative rates and cumulative risks
were also calculated (Day, 1992). Trends for changes in annual ASR
were analysed by single linear regression. Survival rates were calcu-
lated using Kaplan–Meier estimation (Kaplan and Meier, 1958).
RESULTS
Incidence
There were 4316 patients aged under 25 years diagnosed with a
first cancer in the study region between 1968 and 1995; 2099 (M:F
1.28:1) children (age < 15 years) and 2217 (M:F 1.23:1) young
adults (age 15–24 years). In addition there were 46 cases of
Langerhans cell histiocytosis (LCH). Number of cases and age-
specific incidence rates by disease type for the period 1968–1995
are shown in Table 1. Of two cases classed as hepatoblastoma in
the 20 to 24 year group only one with carcinoid syndrome had
central review of pathology; it was compatible with a primary
hepatoma though metastases from a distant site could not be
completely ruled out. The ‘other specified sarcomas’ (group IXd)
composed of synovial sarcoma (25), leiomyosarcoma (11), soft
tissue Ewing’s/pPNET (10), hemangiopericytoma (4), myxoid
liposarcoma (3), hemangiosarcoma (3), myxosarcoma (2), pleo-
morphic liposarcoma (2), clear cell sarcoma (2), alveolar soft part
sarcoma (2), other unique sarcomas (12). In the non-melanoma
skin carcinoma (Group XIe) basal cell carcinoma was the most
frequent type (n = 40) with squamous cell carcinoma accounting
for six cases. The principle sites of the ‘other and unspecified
carcinomas’ (group XIf5) were carcinoma of unknown primary
(ICDO C80.9 n = 18), urethra and other urinary organs 
(C68  n = 17), salivary glands (C8 n = 10), small intestine (C17 
n = 7) and mediastinum (C38 n = 7). The remaining 53 carcinomas
were from a heterogeneous range of sites each with fewer than 
five cases.
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Figure 1 The study region covered by the Northern Region Young Persons’ Malignant Disease RegistryCancer in children and young adults in the north of England 399
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Table 1 Number of cases and incidence rates by disease type for the period 1968–1995 per million per year
Number of cases Incidence rates (per million; per year) Gender
Age-group (years) Age-group (years) ASR ASR ratio
Diagnostic Group 0– 1–4 5–9 10–14 15–19 20–24 0– 1–4 5–9 10–14 15–19 20–24 CUM 0–14 15–24 M:F
I Leukaemia 32 324 190 130 150 103 28.3 69.4 30.9 20.5 24.0 16.4 765 39.6 20.4 1.38
a Lymphoid leukaemia 21 292 161 94 82 43 18.6 62.6 26.2 14.8 13.1 6.8 574 33.6 10.2 1.36
b Acute non-lymphocytic 9 28 26 29 54 41 8.0 6.0 4.2 4.6 8.6 6.5 152 5.2 7.6 1.37
c Chronic myeloid 1 2 2 5 9 15 0.9 0.4 0.3 0.8 1.4 2.4 27 0.5 1.9 2.09
d Other specified 0 1 1 1 2 0 0.0 0.2 0.2 0.2 0.3 0.0 4 0.2 0.2 0.25
e Unspecified 1 1 0 1 3 4 0.9 0.2 0.0 0.2 0.5 0.6 8 0.2 0.6 2.33
II Lymphomas 2 31 73 97 243 332 1.8 6.6 11.9 15.3 38.9 52.8 623 10.5 45.4 1.87
a Hodgkin’s disease 0 4 27 54 176 258 0.0 0.9 4.4 8.5 28.2 41.1 414 4.2 34.2 1.78
b Non-Hodgkin’s 2 26 42 41 64 63 1.8 5.6 6.8 6.5 10.2 10.0 192 5.9 10.1 2.05
c Burkitt’s lymphoma 0 0 2 1 1 3 0.0 0.0 0.3 0.2 0.2 0.5 6 0.2 0.3 2.50
d Misc. lymphoreticular 0 0 1 1 0 1 0.0 0.0 0.2 0.2 0.0 0.2 2 0.1 0.1 0.67
e Unspecified lymphomas 0 1 1 0 2 7 0.0 0.2 0.2 0.0 0.3 1.1 9 0.1 0.7 4.50
III CNS tumours 42 148 168 137 141 176 37.2 31.7 27.3 21.6 22.6 28.0 662 27.8 25.1 1.29
a Ependymoma 14 16 15 8 13 9 12.4 3.4 2.4 1.3 2.1 1.4 62 3.2 1.8 2.75
b Astrocytoma 6 50 52 52 47 52 5.3 10.7 8.5 8.2 7.5 8.3 210 8.8 7.9 1.25
c Pnet 7 37 26 19 6 11 6.2 7.9 4.2 3.0 1.0 1.8 88 5.2 1.3 1.74
d Other gliomas 5 16 18 11 21 33 4.4 3.4 2.9 1.7 3.4 5.3 85 2.9 4.3 1.21
e Other specified 4 13 13 30 38 48 3.5 2.8 2.1 4.7 6.1 7.6 118 3.2 6.8 1.26
f Unspecified 6 16 44 17 16 23 5.3 3.4 7.2 2.7 2.6 3.7 99 4.6 3.1 0.74
IV Sympathetic nervous system 35 79 21 8 5 5 31.0 16.9 3.4 1.3 0.8 0.8 130 9.1 0.8 1.28
a Neuroblastoma 35 74 20 6 5 2 31.0 15.9 3.3 0.9 0.8 0.3 121 8.6 0.6 1.25
b Other 0 5 1 2 0 3 0.0 1.1 0.2 0.3 0.0 0.5 9 0.5 0.2 1.75
V Retinoblastoma 31 44 0 0 0 0 27.5 9.4 0.0 0.0 0.0 0.0 65 5.0 0.0 0.67
VI Renal tumours 15 80 20 4 3 9 13.3 17.1 3.3 0.6 0.5 1.4 111 7.6 0.9 0.87
a Wilms’ & clear cell sarcoma 15 80 20 3 0 1 13.3 17.1 3.3 0.5 0.0 0.2 101 7.5 0.1 0.86
b Renal Ccarcinoma 0 0 0 1 3 8 0.0 0.0 0.0 0.2 0.5 1.3 10 0.0 0.9 1.00
VII Hepatic tumours 5 7 1 1 3 4 4.4 1.5 0.2 0.2 0.5 0.6 18 0.9 0.6 0.62
a Hepatoblastoma 5 5 0 1 0 2 4.4 1.1 0.0 0.2 0.0 0.3 11 0.7 0.1 0.44
b Hepatic carcinoma 0 2 1 0 3 2 0.0 0.4 0.2 0.0 0.5 0.3 7 0.2 0.4 1.00
VIII Bone tumours 0 7 19 74 92 43 0.0 1.5 3.1 11.7 14.7 6.8 188 4.9 11.0 1.59
a Osteosarcoma 0 4 10 45 53 19 0.0 0.9 1.6 7.1 8.5 3.0 105 2.9 5.9 1.43
b Chondrosarcoma 0 0 1 3 4 7 0.0 0.0 0.2 0.5 0.6 1.1 12 0.2 0.9 2.00
c Ewing’s sarcoma 0 3 8 25 30 15 0.0 0.6 1.3 3.9 4.8 2.4 65 1.8 3.7 1.89
d Other specified 0 0 0 0 4 2 0.0 0.0 0.0 0.0 0.6 0.3 5 0.0 0.5 1.40
e Unspecified 0 0 0 1 1 0 0.0 0.0 0.0 0.2 0.2 0.0 2 0.0 0.1 1.00
IX Soft tissue sarcomas 9 48 45 33 56 51 8.0 10.3 7.3 5.2 9.0 8.1 197 7.7 8.6 1.14
a Rhabdomyosarcoma 2 40 31 11 21 5 1.8 8.6 5.0 1.7 3.4 0.8 91 4.9 2.2 1.29
b Fibrosarcoma, neurofibrosarcoma 6 3 6 5 12 16 5.3 0.6 1.0 0.8 1.9 2.5 39 1.2 2.2 0.85
d Other specified 1 5 8 15 20 27 0.9 1.1 1.3 2.4 3.2 4.3 61 1.5 3.7 1.16
e Unspecified 0 0 0 2 3 3 0.0 0.0 0.0 0.3 0.5 0.5 6 0.1 0.5 1.67
X Germ cell/gonadal 14 31 7 18 80 227 12.4 6.6 1.1 2.8 12.8 36.1 303 4.2 23.8 1.83
a Intracranial germ cell 1 1 3 8 4 4 0.9 0.2 0.5 1.3 0.6 0.6 17 0.7 0.6 1.10
b Other non-gonadal germ cell 6 10 1 1 8 22 5.3 2.1 0.2 0.2 1.3 3.5 39 1.2 2.3 0.60
c1 Testes seminoma* 0 0 0 0 2 33 0.0 0.0 0.0 0.0 0.6 10.4 55 0.0 5.2 –
c2 Testes endodermal* 6 18 0 0 1 6 10.4 7.5 0.0 0.0 0.3 1.9 51 3.1 1.1 –
c3 Testes Teratoma* 1 1 1 0 42 102 1.7 0.4 0.3 0.0 13.3 32.2 233 0.4 22.2 –
c4 Ovary germ cell* 0 0 2 9 8 11 0.0 0.0 0.7 2.9 2.6 3.5 49 1.1 3.0 –
d Gonadal Ccarcinoma 0 0 0 0 13 41 0.0 0.0 0.0 0.0 2.1 6.5 43 0.0 4.2 0.02
e Other and unspecified 0 1 0 0 2 8 0.0 0.2 0.0 0.0 0.3 1.3 9 0.1 0.8 0.10
XI Carcinomas 4 11 10 39 124 360 3.5 2.4 1.6 6.2 19.8 57.3 438 3.3 37.5 0.52
a Adrenocortical 1 1 0 0 1 1 0.9 0.2 0.0 0.0 0.2 0.2 3 0.1 0.2 1.00
b Thyroid 0 2 3 7 24 35 0.0 0.4 0.5 1.1 3.8 5.6 57 0.6 4.7 0.48
c Nasopharyngeal 0 1 1 4 6 8 0.0 0.2 0.2 0.6 1.0 1.3 16 0.3 1.1 1.00
d Malignant melanoma 2 3 1 10 41 89 1.8 0.6 0.2 1.6 6.6 14.2 117 0.8 10.1 0.49
e Skin carcinoma 0 0 0 5 11 32 0.0 0.0 0.0 0.8 1.8 5.1 38 0.2 3.3 0.78
f1 Lung carcinoma 0 0 1 1 6 10 0.0 0.0 0.2 0.2 1.0 1.6 14 0.1 1.3 2.00
f2 Breast carcinoma* 0 0 0 0 1 33 0.0 0.0 0.0 0.0 0.3 10.6 55 0.0 5.2 –
f3 Colorectal carcinoma 0 0 0 1 11 16 0.0 0.0 0.0 0.2 1.8 2.5 22 0.0 2.1 2.50
f4 Cervical carcinoma* 0 0 0 0 1 66 0.0 0.0 0.0 0.0 0.3 21.2 107 0.0 10.1 –
f5 Other and unspecified 1 4 4 11 22 70 0.9 0.9 0.7 1.7 3.5 11.1 90 1.0 7.1 0.90
XII XII Other and unspecified 0 0 3 2 5 5 0.0 0.0 0.5 0.3 0.8 0.8 12 0.2 0.8 0.50
a Other specified 0 0 1 0 1 3 0.0 0.0 0.2 0.0 0.2 0.5 4 0.1 0.3 0.25
b Unspecified 0 0 2 2 4 2 0.0 0.0 0.3 0.3 0.6 0.3 8 0.2 0.5 0.67
XIII Langerhan’s cell histiocytosis 9 15 9 9 0 4 8.0 3.2 1.5 1.4 0.0 0.6 38 2.5 0.3 1.15
Males* ** 103 432 328 317 528 695 177.9 180.4 103.8 97.3 167.1 219.6 3839 131.4 191.8 –
Females* ** 86 378 229 226 374 620 156.3 166.4 76.5 73.4 121.0 198.8 3170 109.6 157.6 –
Total** 189 810 557 543 902 1315 167.4 173.6 90.5 85.7 144.3 209.3 3511 120.8 174.9 1.25
* Gender specific incidence rates. ** Excludes Langerhan’s cell histiocytosis. No cases of Kaposi’s sarcoma (group IXc) were recorded. The cases classed as Burkitt’s lymphoma were
diagnosed exclusively after 1982 probably reflecting advances in histopathological classification hence this group is likely to be underrepresented in this series.400 SJ Cotterill et al
British Journal of Cancer (2000) 83(3), 397–403 © 2000 Cancer Research Campaign
1970 1975 1980 1985 1990 1995
Year
0
50
100
150
A
S
R
,
 
p
e
r
 
m
i
l
l
i
o
n
 
c
h
i
l
d
r
e
n
,
 
p
e
r
 
y
e
a
r
All cancers
combined
Solid tumours
Haematological
malignancies
Figure 2 Temporal changes in annual ASRs for the 0 to 14 year age-group by type of cancer.
Note: Data excludes LCH. Regression line shown for all cancers combined shows an increase in ASR by 12.2 per decade (95% CI 6.2 to 18.2). Solid tumours
shows an increase in ASR by 8.6 per decade (95% CI 3.2 to 13.9). Haematological malignancies shows an increase in ASR by 3.6 per decade (95% CI-0.4 to 7.6)
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Figure 3 Temporal changes in annual ASRs for the 15–24 age-group by type of cancer.
Note: Data excludes LCH. Regression line shown for all cancers combined shows an increase in ASR by 16 per decade (95% CI 5 to 27). Solid tumours shows an
increase in ASR by 11 per decade (95% CI 1 to 20). Haematological malignancies shows an increase in ASR by 5 per decade (95% CI to 10)From 1968 to 1995 there were 32 million person years at risk for
the 0 to 24 year age group. The age-standardized rates over the
28-year period for all cancers combined were 121 per million per
year (95% confidence interval (CI) 116–126) for children, and 175
per million per year (95% CI 167–183) for young adults. Incidence
rates (per million per year) varied by age-group; 167 for infants,
174 for 1–4 years, 91 for 5–9 years, 86 for 10–14 years, 144 for
15–19 years and 209 for 20–24 years. The cumulative incidence
rate for cancer up to the age of 25 years was 3511 per million; i.e.
a cumulative risk of 1 in 285. The ASR for childhood cancer in
males was 131 per million children per year and 110 for females.
For young adults (15–24 years) it was 192 for males and 158
for females.
There was a significant increase in the incidence of childhood
cancers over the period (Figure 2); overall ASRs increased by 12
per million per decade (P < 0.001). Incidence of cancer in young
adults increased over time (Figure 3) at a rate of 16 per million
per decade (P % 0.008).
Follow-up
Median follow-up of the 2311 surviving patients was 12 years
(range 1–31 years). For 2286 survivors the latest follow-up date
was within 2 years of the date of analysis. Of those diagnosed
prior to 1992 there were only eight with fewer than 5 years
follow-up.
Survival (Figure 4)
Five-year survival rates for children (0–14 years) over the time
periods 1968–1977, 1978–1987, 1988–1995 were 42% (95% CI
38–45%), 57% (95% CI 54–61%) and 71% (95% CI 67–75%)
respectively. For haematological malignancies 5-year survival
rates over the three periods were 30% (95% CI 25–35%), 60%
(95% CI 54–65%) and 77% (95% CI 71–82%) respectively.
Survival rates for solid tumours were 41% (95% CI 37–46%), 56%
(95% CI 51–60%) and 67% (95% CI 63–72%) respectively.
Five-year survival rates for young adults (15–24 years) over the
three time periods 1968–1977, 1978–1987, 1988–1995 for all
cancers were 45% (95% CI 42–49%), 62% (95% CI 58–65%) and
73% (95% CI 70–78%) respectively. For haematological malig-
nancies 5-year survival rates over the three periods were 44%
(95% CI 38–50%), 67% (95% CI 61–71%) and 72% (95% CI
66–78%) respectively. For solid tumours the rates were 46% (95%
CI 41–51%), 58% (95% CI 54–62%) and 75% (95% CI 70–79%)
respectively.
DISCUSSION
Comprehensive cancer registration is a prerequisite for the effec-
tive planning of health services and evaluation of treatment effi-
cacy. It also forms the basis for epidemiological studies which may
lead to understanding of the aetiology of cancer. National
registries give a broad picture of the situation but their data is
Cancer in children and young adults in the north of England 401
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Figure 4 Survival by time period for children and young adultsrarely as detailed or timely as is possible within a local registry.
The NRYPMDR was one of the first population-based registries
for childhood cancer and is the only registry in the UK having
specialist information on the 15 to 24 year age group. It imple-
ments rigorous procedures to ensure that ascertainment is as
complete as possible; cases are identified from multiple sources.
Cancers in children have been registered prospectively from the
onset of the registry in 1968 whilst the data on young adults were
obtained retrospectively in 1985 in a very comprehensive exercise
and have been collected prospectively since then. Small but signif-
icant increases in incidence over time are reported for both chil-
dren and young adults. It is possible that there may have been
under-ascertainment of young adults in the early period. However,
the steady increase in incidence over time suggests a genuine
increase in the underlying incidence of malignant disease
(Figure 3).
Childhood cancer
There were 2099 cases of cancer registered in children aged
0–14 years over the period 1968–1995 included in this study.
Incidence rates for childhood cancer in the study region are gener-
ally similar to those reported by the UK National Registry of
Childhood Cancers and to those in other Western populations
(Parkin et al, 1988). The most common type of cancer was acute
lymphoblastic leukaemia, accounting for 31% of cases with CNS
tumours (23%) and forming the second largest group.
This report suggests a small but significant increase in the
incidence of childhood cancer in the Northern Region, which is
unlikely to be entirely accounted for by under-ascertainment in the
early period: registration rates for paediatric cancers are consid-
ered to be in excess of 98%. The registry has consistently identi-
fied cases from multiple sources and treatment is centralized.
Increased incidence is consistent with other population-based
reports. Data from the USA indicated trends of increasing inci-
dence of childhood cancer (Gurney et al, 1996), particularly in
infants (Gurney et al, 1998; Kenney et al, 1998). There have been
reports of increased incidence of specific tumours in the UK for
neuroblastoma (Stiller, 1993) and leukaemia (Blair and Birch,
1994). The aetiology of childhood cancers remains largely
unknown; only about 5% are thought to have an inherited genetic
component (Narod et al, 1991). The increasing incidence of child-
hood cancer is consistent with the hypothesis that environmental
factors play a role in the aetiology of these diseases. There is
considerable evidence that the risk of childhood leukaemia in
particular is influenced by characteristics of the environment, such
as population mixing (Kinlen, 1995; Dickinson and Partier, 1999).
For solid tumours the route by which the environment influences
the risk of disease is unclear. The dramatic improvements in
survival over the period mirror national and international trends in
outcome (Stiller, 1994).
Young adults
There is little published specifically concerning cancer incidence
and survival in young adults, particularly in 20  to 24 year age
group, with a few notable exceptions. This population-based study
recorded 2217 cancers diagnosed in young adults. Lymphomas
were the largest diagnostic group (26% of cases), with Hodgkin’s
disease being the most frequent diagnosis. Leukaemias accounted
for 13% of cases and the proportions of acute myeloid and chronic
myeloid types were higher than in children (38% and 9% vs 14%
and 1% respectively).
There have been a small number of other population based
reports including 15 to 19 year-olds. A study of cancer in Nordic
countries (Tulinius et al, 1992) during 1981–1986 reported that
incidence and distribution of cancer types in adolescents were
similar to those seen in the North of England. In a study of adoles-
cents (10–19 years) in New South Wales (Fritschi et al, 1995) over
the period 1972–1991 incidence in the 15 to 19-year group was
higher than in the North of England (rates per million per year:
males 202 vs 167 and females 186 vs 121). This difference was
largely due to the well known higher incidence of malignant
melanoma which accounted for 27% of the Australian cases
compared to 5% of cases in the North of England. A report from
the SEER programme (Smith et al, 1999), for 1975–1994 also
found higher overall incidence for 15- to 19-year-olds (rates 202
vs 144). Rates were similar for ALL (13 vs 13 per million, per
year), AML (9 vs 9), Hodgkin’s disease (33 vs 28), CNS (20 vs
23). However, SEER reported higher rates for germ-cell/gonadal
(31 vs 13), thyroid cancer (15 vs 4), soft tissue sarcoma (16 vs 9),
melanoma (14 vs 7) and NHL (15 vs 10). In common with the
North of England the SEER data indicated a trend for increasing
incidence of cancers in the 15 to 19 year-olds. Those cancers for
which the differences in incidence rates were greatest included
tumours which have been reported to be increasing in incidence
(testicular cancer, melanoma and NHL) (Brown et al, 1987; Elder,
1995; Cartwright et al, 1999). Different racial characteristics of the
populations may also affect the incidence of some types of cancer.
Studies of 10- to 19-year-olds in Denmark (Martos et al, 1993)
during 1943–1987 and Vaud in Switzerland (Levi et al, 1995) in
1974–1992 also found trends for increasing incidence of cancer in
adolescents.
The diverse range of solid tumours in young adults may be cate-
gorized into three broad groups: (1) ‘late’ paediatric type cancers
(groups IIIc, IV, VIa, VIIa, IXa), (2) ‘age-specific’ cancers for
adolescents and young adults (groups VIII, Xc), and (3) ‘early
onset’ carcinomas (group XI). The ‘late’ paediatric cancers
normally associated with childhood included rhabdomyosarcoma
(26 cases), medulloblastoma (14), neuroblastoma (seven), hepato-
blastoma (two) and Wilms’ tumour (one). There have been other
anecdotal reports of such ‘late’ paediatric cancers in adult patients
(Hollowood and Fletcher, 1994; Hentrich et al, 1995; Paterson and
Walker, 1995; Moody et al, 1996; Varona and Ruiz, 1996). The
cancers which are ‘largely specific’ to adolescents and young
adults include bone tumours and testicular cancer. Bone tumours
have a peak incidence between the ages of 10 and 20 years and
accounted for 6% of cancers in young adults in this series;
osteosarcoma and particularly Ewing’s sarcoma are less common
in patients older than 25 years (Dortman and Czerniak, 1995).
Testicular cancer is most common in men in thier 20s; most of the
men in this series had histological diagnoses of teratoma or semi-
noma while endodermal testicular cancer tended to predominate in
boys aged under 15 years. There are many ‘early onset’ carci-
nomas arising in a wide range of anatomical sites. These include
skin cancer (173 cases) with malignant melanoma being the most
common type, thyroid carcinoma (59) and nasopharyngeal carci-
noma (14). There are also carcinomas that are considered rare in
young adults, particularly carcinomas of the breast (34), cervix
(67), gastrointestinal system (43) and lung (16). The aetiology of
these ‘early onset’ carcinomas remains largely unknown, though it
is likely that there will be an inherited component.
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the 28-year period, those diagnosed during 1988–1995 having a
5-year survival rate of 73% (95% CI 70–78). Improvements in
survival in young adults have matched those seen in children and
suggest that either many of the tumours of early adulthood are
intrinsically more curable than those in older adults or that young
adults receive more concentrated and effective treatment than is
offered to many older adults, or a combination of the two. Those
cancers with particularly good prognosis in this age-group include
Hodgkin’s disease, testicular cancer, thyroid carcinoma and non-
melanoma skin cancer. For the cohort diagnosed between 1988
and 1995 the 5-year survival for Hodgkin’s disease was 87%,
(95% CI 80–93), testicular cancer 87% (95% CI 81–94), and at
time of analysis there had been no deaths from thyroid carcinoma
or non-melanoma skin cancers.
The number of survivors of cancer during childhood and early
adulthood has increased and in this series 2088 survived at least
5 years. By the year 2025 approximately 1 in 400 of the adult
population will be a survivor of cancer diagnosed before the age
25 years. The improvements in survival draw attention to the
steadily growing population in whom study of psycho-social and
other long-term effects for treatment of cancer is needed. Although
there is considerable published and on-going research into late
effects of treatment for childhood cancer, less is documented about
late effects of treatment given to young adults. Specific studies of
the late effects of diagnosis and treatment for cancer in young
adults may be needed. The increase in incidence in the Northern
region is cause for concern and requires further investigation.
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